New treatment for rare motor neurone disease recommended for approval
Submitted by Anonymous (not verified) on 23 February 2024 - 11:00
New treatment for rare motor neurone disease recommended for approval
First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria
Submitted by Anonymous (not verified) on 23 February 2024 - 11:00
First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria
Committee for Medicinal Products for Veterinary Use (CVMP): 16-18 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 January 2024 to 18 January 2024
Submitted by Anonymous (not verified) on 23 February 2024 - 10:19
Committee for Medicinal Products for Veterinary Use (CVMP): 16-18 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 January 2024 to 18 January 2024
Non-clinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID-19 - Scientific guideline
Submitted by Anonymous (not verified) on 22 February 2024 - 10:51
Non-clinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID-19 - Scientific guideline
EMEA-001757-PIP02-15-M03
Submitted by Anonymous (not verified) on 22 February 2024 - 9:28
EMEA-001757-PIP02-15-M03
Procedural advice on the accelerated assessment of marketing authorisation applications pursuant to Article 44 (3) of Regulation (EU) No 2019/6
Submitted by Anonymous (not verified) on 22 February 2024 - 9:26
Procedural advice on the accelerated assessment of marketing authorisation applications pursuant to Article 44 (3) of Regulation (EU) No 2019/6
Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0043
Submitted by Anonymous (not verified) on 21 February 2024 - 16:36
Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0043
Valproate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0043
Submitted by Anonymous (not verified) on 21 February 2024 - 16:35
Valproate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0043
Valproate : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0043
Submitted by Anonymous (not verified) on 21 February 2024 - 16:28
Valproate : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0043
Herbal medicinal product: Fumariae herbaArray, F: Assessment finalised
Submitted by Anonymous (not verified) on 21 February 2024 - 15:11
Herbal medicinal product: Fumariae herbaArray, F: Assessment finalised